Advance Search
You have access

Development and Characterization of Buccal Film: Tacrolimus as A Model Drug

Cite this:
P, A., R, A., R, R., Anil, A., & A Surendran, S. (2019). Development and Characterization of Buccal Film: Tacrolimus as A Model Drug. Journal of Medical Biomedical and Applied Sciences, 7(1), 207–211. https://doi.org/10.15520/jmbas.v7i1.176
Copyright @ 2022 Interactive Protocols
RIGHTS & PERMISSIONS
Article Views
660
Altmetric
1
Citations
-
LEARN ABOUT THESE METRICS
pdf   xml  

Abstract

Buccal drug delivery has become a relevant route of administration. It has got various advantages, masking the first
pass metabolism being the primary one, thus ensuring increased drug bioavailability at the site of action. Tacrolimus,
an immunosuppressant, calcineurin inhibitor is the drug of choice. Oral tablet suffers from high first pass metabolism
and topical formulations such as ointments readily washout from the site of application. Tacrolimus formulated as
mucoadhesive buccal film provided prolonged effect than topical formulations. Films (F1 & F2) were prepared by
solvent casting technique. Chitosan being the best mucoadhesive polymer with wound healing properties increased the
retention time of the film at the wound site. HPMC ensured good film property. Propylene glycol was used as plasticizer
and citric acid as salivary stimulator and cross linker. The compatibility of drug in the formulation was confirmed by
FTIR. Formulated films were subjected to various evaluation parameters, and all the physical parameters were within
the acceptable limits. In vitro release was found to be better for F1. Ex vivo studies of F1 using goat mucous showed a
permeation of 76.5%.

KEYWORDS:

 Additional Information

Downloads

Download data is not yet available.

Article Metrics Graph

Chart Graph | Range Graph

Content

Section

Source

Indexing and Abstracting

  • 1
  • 2
  • 3
  • 4
  • 5
Google Scholar Url for the Journal is not available